Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes

Cancer Letters

Volumn 378, Issue 2, 2016, Pages 69-79

  Wang, Junjian ^a   Duan, Zhijian ^a   Nugent, Zoann ^b   Zou, June X ^a   Borowsky, Alexander D ^a   Zhang, Yanhong ^a   Tepper, Clifford G ^a   Li, Jian Jian ^a   Fiehn, Oliver ^c   Xu, Jianzhen ^d   Kung, Hsing Jien ^a,e   Murphy, Leigh C ^b   Chen, Hong Wu ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Histone methyltransferase; Metabolism; NSD2; Pentose phosphate pathway; Tamoxifen resistance

Indexed keywords

HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE MMSET; HISTONE METHYLTRANSFERASE NSD2; HISTONE METHYLTRANSFERASE WHSCI; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; HISTONE LYSINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; REPRESSOR PROTEIN; WHSC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; ENZYME METABOLISM; EPIGENETICS; GENE EXPRESSION PROFILING; GLYCOLYSIS; HISTONE METHYLTRANSFERASE METABOLISM; IMMUNOHISTOCHEMISTRY; MCF 7 CELL LINE; MOUSE; NONHUMAN; PENTOSE PHOSPHATE CYCLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; TUMOR XENOGRAFT; WILD TYPE; AGONISTS; ANIMAL; BINDING SITE; BREAST NEOPLASMS; C57BL MOUSE; DNA METHYLATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; KAPLAN MEIER METHOD; MCF-7 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; NUCLEAR REPROGRAMMING; NUDE MOUSE; PROMOTER REGION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BINDING SITES; BREAST NEOPLASMS; CELLULAR REPROGRAMMING; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; KAPLAN-MEIER ESTIMATE; MCF-7 CELLS; MICE, INBRED C57BL; MICE, NUDE; MIDDLE AGED; NADP; PENTOSE PHOSPHATE PATHWAY; PROMOTER REGIONS, GENETIC; REACTIVE OXYGEN SPECIES; REPRESSOR PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TAMOXIFEN; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969134879     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.05.004     Document Type: Article

References (43)

1. Riganti C., Gazzano E., Polimeni M., Aldieri E., Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic. Biol. Med 2012, 53:421-436.
2. Jiang P., Du W., Wang X., Mancuso A., Gao X., Wu M., et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol 2011, 13:310-316.
3. Ying H., Kimmelman A.C., Lyssiotis C.A., Hua S., Chu G.C., Fletcher-Sananikone E., et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 2012, 149:656-670.
4. Duvel K., Yecies J.L., Menon S., Raman P., Lipovsky A.I., Souza A.L., et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 2010, 39:171-183.
5. Dong C., Yuan T., Wu Y., Wang Y., Fan T.W., Miriyala S., et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell 2013, 23:316-331.
6. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
7. Cheung E.C., Ludwig R.L., Vousden K.H. Mitochondrial localization of TIGAR under hypoxia stimulates HK2 and lowers ROS and cell death. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:20491-20496.
8. Cheung E.C., Athineos D., Lee P., Ridgway R.A., Lambie W., Nixon C., et al. TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev. Cell 2013, 25:463-477.
9. Cheung E.C., Lee P., Ceteci F., Nixon C., Blyth K., Sansom O.J., et al. Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine. Genes Dev 2016, 30:52-63.
10. Patra K.C., Wang Q., Bhaskar P.T., Miller L., Wang Z., Wheaton W., et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013, 24:213-228.
11. Wolf A., Agnihotri S., Micallef J., Mukherjee J., Sabha N., Cairns R., et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J. Exp. Med 2011, 208:313-326.
12. Lauring J., Abukhdeir A.M., Konishi H., Garay J.P., Gustin J.P., Wang Q., et al. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood 2008, 111:856-864.
13. Marango J., Shimoyama M., Nishio H., Meyer J.A., Min D.J., Sirulnik A., et al. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor. Blood 2008, 111:3145-3154.
14. Hudlebusch H.R., Santoni-Rugiu E., Simon R., Ralfkiær E., Rossing H.H., Johansen J.V., et al. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin. Cancer Res 2011, 17:2919-2933.
15. Yang P., Guo L., Duan Z.J., Tepper C.G., Xue L., Chen X., et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol. Cell. Biol 2012, 32:3121-3131.
16. Popovic R., Martinez-Garcia E., Giannopoulou E.G., Zhang Q., Zhang Q., Ezponda T., et al. Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 2014, 10:e1004566.
17. Ezponda T., Popovic R., Shah M.Y., Martinez-Garcia E., Zheng Y., Min D.J., et al. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. Oncogene 2013, 32:2882-2890.
18. Martinez-Garcia E., Popovic R., Min D.J., Sweet S.M., Thomas P.M., Zamdborg L., et al. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood 2011, 117:211-220.
19. Feng Q., Zhang Z., Shea M.J., Creighton C.J., Coarfa C., Hilsenbeck S.G., et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res 2014, 24:809-819.
20. Jeselsohn R., Buchwalter G., De Angelis C., Brown M., Schiff R. ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat. Rev. Clin. Oncol 2015, 12:573-583.
21. Yi W., Clark P.M., Mason D.E., Keenan M.C., Hill C., Goddard W.A., et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 2012, 337:975-980.
22. Zou J.X., Duan Z., Wang J., Sokolov A., Xu J., Chen C.Z., et al. Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol. Cancer Res 2014, 12:539-549.
23. Razandi M., Pedram A., Jordan V.C., Fuqua S., Levin E.R. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene 2013, 32:3274-3285.
24. Ding J., Li T., Wang X., Zhao E., Choi J.-H., Yang L., et al. The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab 2013, 18:896-907.
25. Zirath H., Frenzel A., Oliynyk G., Segerstrom L., Westermark U.K., Larsson K., et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:10258-10263.
26. Van Schaftingen E., Lederer B., Bartrons R., Hers H.G. A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. Eur. J. Biochem 1982, 129:191-195.
27. Anastasiou D., Poulogiannis G., Asara J.M., Boxer M.B., Jiang J.K., Shen M., et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 2011, 334:1278-1283.
28. Meissen J.K., Yuen B.T., Kind T., Riggs J.W., Barupal D.K., Knoepfler P.S., et al. Induced pluripotent stem cells show metabolomic differences to embryonic stem cells in polyunsaturated phosphatidylcholines and primary metabolism. PLoS ONE 2012, 7. e46770.
29. Kalashnikova E.V., Revenko A.S., Gemo A.T., Andrews N.P., Tepper C.G., Zou J.X., et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010, 70:9402-9412.
30. Snell L., Watson P.H. Breast tissue banking: collection, handling, storage, and release of tissue for breast cancer research. Methods Mol. Med 2006, 120:3-24.
31. Shrivastav A., Bruce M., Jaksic D., Bader T., Seekallu S., Penner C., et al. The mechanistic target for rapamycin pathway is related to the phosphorylation score for estrogen receptor-alpha in human breast tumors in vivo. Breast Cancer Res 2014, 16:R49.
32. Gyorffy B., Lanczky A., Eklund A.C., Denkert C., Budczies J., Li Q., et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat 2010, 123:725-731.
33. Brünner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 1997, 57:3486-3493.
34. Bosco E.E., Wang Y., Xu H., Zilfou J.T., Knudsen K.E., Aronow B.J., et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J. Clin. Invest 2007, 117:218-228.
35. Chanrion M., Negre V., Fontaine H., Salvetat N., Bibeau F., Mac Grogan G., et al. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin. Cancer Res 2008, 14:1744-1752.
36. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 2008, 68:826-833.
37. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med 2011, 62:233-247.
38. Jin K., Park S., Teo W.W., Korangath P., Cho S.S., Yoshida T., et al. HOXB7 is an ERα cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov 2015, 5:944-959.
39. Asangani I.A., Ateeq B., Cao Q., Dodson L., Pandhi M., Kunju L.P., et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol. Cell 2013, 49:80-93.
40. Gallo M., Coutinho F.J., Vanner R.J., Gayden T., Mack S.C., Murison A., et al. MLL5 orchestrates a cancer self-renewal state by repressing the histone variant H3.3 and globally reorganizing chromatin. Cancer Cell 2015, 28:715-729.
41. Nin D.S., Yew C.W., Tay S.K., Deng L.-W. Targeted silencing of MLL5β inhibits tumor growth and promotes gamma-irradiation sensitization in HPV16/18-associated cervical cancers. Mol. Cancer Ther 2014, 13:2572-2582.
42. Pinheiro I., Margueron R., Shukeir N., Eisold M., Fritzsch C., Richter F.M., et al. Prdm3 and Prdm16 are H3K9me1 methyltransferases required for mammalian heterochromatin integrity. Cell 2012, 150:948-960.
43. Jo A., Mitani S., Shiba N., Hayashi Y., Hara Y., Takahashi H., et al. High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia 2015, 29:1076-1083.